Skip to main content
. Author manuscript; available in PMC: 2024 Mar 1.
Published in final edited form as: Ann Surg. 2021 Aug 13;277(3):e538–e544. doi: 10.1097/SLA.0000000000005163

Table 4.

Observed rates of unadjusted intraoperative and postoperative outcomes

Outcome Induction FOLFOX vs. CP Induction Chemotherapy vs. No Induction
FOLFOX (n=70) CP (n=239) P Induction (n=309) No Induction (n=142) P
Length of stay, days 9 (6 to 28) 10 (5 to 144) <0.001 10 (5 to 144) 10 (1 to 71) 0.86
Minimally invasive 46 (66) 105 (44) 0.002 151 (49) 60 (42) 0.22
R1 resection 1 (1) 11 (5) 0.31 12 (4) 4 (3) 0.79
Serious complication 12 (17) 41 (17) >0.99 53 (17) 29 (20) 0.43
In-hospital mortality 0 (0) 7 (3) 0.36 7 (2) 2 (1) 0.73
30-day mortality 0 (0) 5 (2) 0.59 5 (2) 2 (1) >0.99
90-day mortality 1 (1) 13 (5) 0.20 14 (5) 4 (3) 0.45

Data are no. (%) or median (range). Fisher’s exact test and the Wilcoxon rank-sum test were used. CP, carboplatin plus paclitaxel.